|
|
| Maladies Infectieuses > Etude de marché sectorielle |
| Lower Detection Limits of HBV DNA Assays |
|
|
|
|
€ 80,00 |
Editeur
: |
TriMark |
Langue
: |
Anglais |
Date de publication : |
Janvier 2006 |
Taille du document : |
1 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Therapeutic Vaccines: More Trials and Tribulations
202 pages | Décembre 2005 |
IntroductionTherapeutic vaccines have faced numerous setbacks in recent years.
The only three vaccines to reach the market have had insignificant sales, while the pipeline has seen numerous high-pr |
6 460,00 €
|
| |
| |
Stakeholder Perspectives: Influenza Vaccines - Flying back Into Flu
166 pages | Décembre 2005 |
IntroductionInfluenza is a highly infectious disease which globally infects 10-20% of the population every year causing up to 500,000 deaths.
Although all persons are at risk, the elderly and the y |
6 460,00 €
|
| |
| |
Lower Detection Limits of HBV DNA Assays
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
The Antivirals Market Outlook: Market analysis of future growth and leading players by sector
178 pages | Janvier 2005 |
Business Insights have teamed up with IMS Health to bring you, ‘The Antivirals Market Outlook: Market analysis of future growth and leading players by sector.’ This unique product offering provides an |
2 443,75 €
|
| |
| |
Human Vaccines
481 pages | Octobre 2005 |
This report analyzes the worldwide markets for Human Vaccines in Millions of US$.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific (excluding Jap |
3 091,00 €
|
| |
| |
Pipeline Insight: Hepatitis C - Small Molecules, Big Revolution
237 pages | Avril 2005 |
IntroductionLess than 50% of chronically infected hepatitis C patients do not benefit from the current standard of care, pegylated interferon plus ribavirin.
In the short-term, the treatment landsc |
9 120,00 €
|
| |
| |
Monoclonal Antibody Therapies: Evolving into a $30 billion market
360 pages | Avril 2005 |
IntroductionThe monoclonal antibody market is one of the fastest growing and most lucrative sectors of the pharmaceutical industry, with exceptional 48.1% growth between 2003 and 2004.
It has the p |
12 160,00 €
|
| |
| |
Antiviral HIV Treatment in Developing Countries Number of Patients
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Pipeline Insight: Hematological malignancies - Targeted treatments and immunotherapy infuse new blood
219 pages | Avril 2005 |
IntroductionGiven an enhanced understanding of the biological basis for oncogenesis and the benefit of immunotherapy approaches such as Genentech/Roche's Rituxan, it is no surprise that targeted treat |
9 120,00 €
|
| |
| |
Pipeline Insight: HIV - Hold Your Horses
216 pages | Avril 2005 |
IntroductionIn the current antiretroviral landscape, resistance in all three of the established classes is proving to be problematic.
Accordingly, current clinical trials are recruiting treatment-r |
9 120,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Lower Detection Limits of HBV DNA Assays |
|
|
This Database Table is a one-page table of hard-to-find numerical information. The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specific data points. The Database Table is NOT a report or a comprehensive analysis.
|
|
|
PPLSEN
|
|
|
|
|
